Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Orvical vs Kaletra (Lopinavir/Ritonavir) in Healthy Volunteers
NCT04386876Phase 1Completed
- Sponsor
- World Medicine
- Start
- Apr 2020
- Primary completion
- May 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lopinavir and ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by World Medicine. Primary endpoint: Primary Pharmacokinetic End Points at 13 weeks. Started Apr 2020; status: completed.
02
Drugs
lopinavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04386876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04386876.